KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) With Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Results of the Phase 2 ZUMA-2 Study
Year: 2019
Type: conference-abstract
Source: Blood
Authors: Michael L. Wang, Javier Munoz, Andre Goy, Frederick L. Locke, Caron A. Jacobson, Brian T. Hill, John M. Timmerman, Houston Holmes, Samantha Jaglowski, Ian W. Flinn, Peter A. McSweeney, David B. Miklos, John M. Pagel, Marie Jose Kersten, Weimin Peng, Lianqing Zheng, John M. Rossi, Rajul K. Jain, Arati V. Rao, Patrick M Reagan
Institutions: The University of Texas MD Anderson Cancer Center, Banner MD Anderson Cancer Center, Hackensack University Medical Center, Moffitt Cancer Center, Dana-Farber Cancer Institute, Cleveland Clinic, University of California, Los Angeles, Texas Oncology, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Sarah Cannon, Colorado Blood Cancer Institute, Stanford Medicine, Stanford University, Amsterdam UMC Location University of Amsterdam, University of Amsterdam, Kite (United States), University of Rochester Medicine, University of Rochester
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2982836758